nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC15A1—epithelium—urinary bladder cancer	0.00578	0.102	CbGeAlD
Ceftazidime—SLC15A1—renal system—urinary bladder cancer	0.00536	0.0942	CbGeAlD
Ceftazidime—SLC15A2—prostate gland—urinary bladder cancer	0.00492	0.0864	CbGeAlD
Ceftazidime—Cefdinir—MPO—urinary bladder cancer	0.00441	0.502	CrCbGaD
Ceftazidime—Cefaclor—MPO—urinary bladder cancer	0.00437	0.498	CrCbGaD
Ceftazidime—SLC22A5—prostate gland—urinary bladder cancer	0.00428	0.0751	CbGeAlD
Ceftazidime—SLC15A2—seminal vesicle—urinary bladder cancer	0.00416	0.0731	CbGeAlD
Ceftazidime—SLC15A1—vagina—urinary bladder cancer	0.00388	0.0682	CbGeAlD
Ceftazidime—SLC22A5—seminal vesicle—urinary bladder cancer	0.00362	0.0636	CbGeAlD
Ceftazidime—SLC15A2—renal system—urinary bladder cancer	0.00335	0.0589	CbGeAlD
Ceftazidime—SLC15A2—urethra—urinary bladder cancer	0.00329	0.0578	CbGeAlD
Ceftazidime—SLC22A5—renal system—urinary bladder cancer	0.00291	0.0512	CbGeAlD
Ceftazidime—SLC22A5—urethra—urinary bladder cancer	0.00286	0.0503	CbGeAlD
Ceftazidime—SLC15A2—female reproductive system—urinary bladder cancer	0.00268	0.0472	CbGeAlD
Ceftazidime—SLC15A2—vagina—urinary bladder cancer	0.00243	0.0427	CbGeAlD
Ceftazidime—SLC22A5—female reproductive system—urinary bladder cancer	0.00233	0.041	CbGeAlD
Ceftazidime—SLC22A5—vagina—urinary bladder cancer	0.00211	0.0371	CbGeAlD
Ceftazidime—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00205	0.0022	CcSEcCtD
Ceftazidime—Skin disorder—Thiotepa—urinary bladder cancer	0.00204	0.00218	CcSEcCtD
Ceftazidime—Erythema multiforme—Etoposide—urinary bladder cancer	0.002	0.00215	CcSEcCtD
Ceftazidime—Vision blurred—Fluorouracil—urinary bladder cancer	0.002	0.00214	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—urinary bladder cancer	0.002	0.00214	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—urinary bladder cancer	0.00199	0.00213	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00198	0.00212	CcSEcCtD
Ceftazidime—Flushing—Etoposide—urinary bladder cancer	0.00197	0.00211	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00197	0.0021	CcSEcCtD
Ceftazidime—Leukopenia—Gemcitabine—urinary bladder cancer	0.00194	0.00207	CcSEcCtD
Ceftazidime—Angiopathy—Etoposide—urinary bladder cancer	0.00192	0.00206	CcSEcCtD
Ceftazidime—Immune system disorder—Etoposide—urinary bladder cancer	0.00192	0.00205	CcSEcCtD
Ceftazidime—Leukopenia—Fluorouracil—urinary bladder cancer	0.0019	0.00204	CcSEcCtD
Ceftazidime—Vision blurred—Cisplatin—urinary bladder cancer	0.0019	0.00203	CcSEcCtD
Ceftazidime—Tremor—Cisplatin—urinary bladder cancer	0.00189	0.00202	CcSEcCtD
Ceftazidime—Paraesthesia—Thiotepa—urinary bladder cancer	0.00188	0.00202	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—urinary bladder cancer	0.00187	0.00201	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—urinary bladder cancer	0.00185	0.00198	CcSEcCtD
Ceftazidime—Convulsion—Fluorouracil—urinary bladder cancer	0.00184	0.00197	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—urinary bladder cancer	0.00184	0.00197	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00184	0.00197	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00183	0.00196	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.00182	0.00195	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00182	0.00195	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00181	0.00194	CcSEcCtD
Ceftazidime—Dysgeusia—Etoposide—urinary bladder cancer	0.00181	0.00193	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—urinary bladder cancer	0.00181	0.00193	CcSEcCtD
Ceftazidime—Leukopenia—Cisplatin—urinary bladder cancer	0.0018	0.00193	CcSEcCtD
Ceftazidime—Pain—Thiotepa—urinary bladder cancer	0.00179	0.00192	CcSEcCtD
Ceftazidime—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00176	0.00189	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—urinary bladder cancer	0.00175	0.00188	CcSEcCtD
Ceftazidime—Convulsion—Cisplatin—urinary bladder cancer	0.00175	0.00187	CcSEcCtD
Ceftazidime—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00173	0.00186	CcSEcCtD
Ceftazidime—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00173	0.00185	CcSEcCtD
Ceftazidime—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00173	0.00185	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00172	0.00184	CcSEcCtD
Ceftazidime—Skin disorder—Gemcitabine—urinary bladder cancer	0.00171	0.00183	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.0017	0.00182	CcSEcCtD
Ceftazidime—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.0017	0.00182	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—urinary bladder cancer	0.0017	0.00182	CcSEcCtD
Ceftazidime—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.0017	0.00182	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.00168	0.0018	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—urinary bladder cancer	0.00167	0.00179	CcSEcCtD
Ceftazidime—Urticaria—Thiotepa—urinary bladder cancer	0.00167	0.00178	CcSEcCtD
Ceftazidime—Body temperature increased—Thiotepa—urinary bladder cancer	0.00166	0.00177	CcSEcCtD
Ceftazidime—Abdominal pain—Thiotepa—urinary bladder cancer	0.00166	0.00177	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00165	0.00177	CcSEcCtD
Ceftazidime—Leukopenia—Etoposide—urinary bladder cancer	0.00165	0.00177	CcSEcCtD
Ceftazidime—Hypotension—Gemcitabine—urinary bladder cancer	0.00165	0.00176	CcSEcCtD
Ceftazidime—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00164	0.00176	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—urinary bladder cancer	0.00162	0.00174	CcSEcCtD
Ceftazidime—Hypotension—Fluorouracil—urinary bladder cancer	0.00162	0.00173	CcSEcCtD
Ceftazidime—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00161	0.00173	CcSEcCtD
Ceftazidime—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00161	0.00172	CcSEcCtD
Ceftazidime—Convulsion—Etoposide—urinary bladder cancer	0.0016	0.00171	CcSEcCtD
Ceftazidime—Skin disorder—Cisplatin—urinary bladder cancer	0.0016	0.00171	CcSEcCtD
Ceftazidime—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00158	0.0017	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—urinary bladder cancer	0.00157	0.00168	CcSEcCtD
Ceftazidime—SLC15A2—lymph node—urinary bladder cancer	0.00157	0.0276	CbGeAlD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00156	0.00167	CcSEcCtD
Ceftazidime—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00156	0.00167	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00155	0.00166	CcSEcCtD
Ceftazidime—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00155	0.00165	CcSEcCtD
Ceftazidime—Hypotension—Cisplatin—urinary bladder cancer	0.00154	0.00164	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00152	0.00163	CcSEcCtD
Ceftazidime—Pain—Gemcitabine—urinary bladder cancer	0.00151	0.00161	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—urinary bladder cancer	0.00151	0.00161	CcSEcCtD
Ceftazidime—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00151	0.00161	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.0015	0.0016	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—urinary bladder cancer	0.00148	0.00159	CcSEcCtD
Ceftazidime—Pruritus—Thiotepa—urinary bladder cancer	0.00148	0.00159	CcSEcCtD
Ceftazidime—Pain—Fluorouracil—urinary bladder cancer	0.00148	0.00159	CcSEcCtD
Ceftazidime—Paraesthesia—Cisplatin—urinary bladder cancer	0.00148	0.00158	CcSEcCtD
Ceftazidime—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00148	0.00158	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—urinary bladder cancer	0.00147	0.00157	CcSEcCtD
Ceftazidime—Skin disorder—Etoposide—urinary bladder cancer	0.00146	0.00157	CcSEcCtD
Ceftazidime—Diarrhoea—Thiotepa—urinary bladder cancer	0.00144	0.00154	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00143	0.00153	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00142	0.00152	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—urinary bladder cancer	0.00141	0.00151	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—urinary bladder cancer	0.00141	0.00151	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—urinary bladder cancer	0.00141	0.00151	CcSEcCtD
Ceftazidime—Hypotension—Etoposide—urinary bladder cancer	0.00141	0.00151	CcSEcCtD
Ceftazidime—Pain—Cisplatin—urinary bladder cancer	0.00141	0.00151	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.0014	0.0015	CcSEcCtD
Ceftazidime—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00139	0.00149	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—urinary bladder cancer	0.00139	0.00149	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—urinary bladder cancer	0.00139	0.00149	CcSEcCtD
Ceftazidime—Dizziness—Thiotepa—urinary bladder cancer	0.00139	0.00148	CcSEcCtD
Ceftazidime—Urticaria—Fluorouracil—urinary bladder cancer	0.00138	0.00147	CcSEcCtD
Ceftazidime—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00137	0.00147	CcSEcCtD
Ceftazidime—SLC22A5—lymph node—urinary bladder cancer	0.00137	0.024	CbGeAlD
Ceftazidime—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00136	0.00146	CcSEcCtD
Ceftazidime—Paraesthesia—Etoposide—urinary bladder cancer	0.00135	0.00145	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00134	0.00143	CcSEcCtD
Ceftazidime—Vomiting—Thiotepa—urinary bladder cancer	0.00133	0.00143	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—urinary bladder cancer	0.00132	0.00142	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—urinary bladder cancer	0.00132	0.00142	CcSEcCtD
Ceftazidime—Rash—Thiotepa—urinary bladder cancer	0.00132	0.00142	CcSEcCtD
Ceftazidime—Dermatitis—Thiotepa—urinary bladder cancer	0.00132	0.00141	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00132	0.00141	CcSEcCtD
Ceftazidime—Headache—Thiotepa—urinary bladder cancer	0.00131	0.00141	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00131	0.00141	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—urinary bladder cancer	0.0013	0.0014	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—urinary bladder cancer	0.0013	0.00139	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.0013	0.00139	CcSEcCtD
Ceftazidime—Body temperature increased—Cisplatin—urinary bladder cancer	0.0013	0.00139	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—urinary bladder cancer	0.00129	0.00138	CcSEcCtD
Ceftazidime—Pain—Etoposide—urinary bladder cancer	0.00129	0.00138	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—urinary bladder cancer	0.00128	0.00138	CcSEcCtD
Ceftazidime—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00128	0.00137	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—urinary bladder cancer	0.00128	0.00137	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—urinary bladder cancer	0.00127	0.00136	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00125	0.00134	CcSEcCtD
Ceftazidime—Pruritus—Gemcitabine—urinary bladder cancer	0.00125	0.00134	CcSEcCtD
Ceftazidime—Nausea—Thiotepa—urinary bladder cancer	0.00125	0.00133	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00124	0.00132	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00123	0.00132	CcSEcCtD
Ceftazidime—Pruritus—Fluorouracil—urinary bladder cancer	0.00123	0.00131	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00123	0.00131	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—urinary bladder cancer	0.00123	0.00131	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00121	0.0013	CcSEcCtD
Ceftazidime—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00121	0.0013	CcSEcCtD
Ceftazidime—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00121	0.00129	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—urinary bladder cancer	0.0012	0.00129	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—urinary bladder cancer	0.0012	0.00129	CcSEcCtD
Ceftazidime—Urticaria—Etoposide—urinary bladder cancer	0.0012	0.00128	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—urinary bladder cancer	0.00119	0.00128	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—urinary bladder cancer	0.00119	0.00128	CcSEcCtD
Ceftazidime—Abdominal pain—Etoposide—urinary bladder cancer	0.00119	0.00127	CcSEcCtD
Ceftazidime—Body temperature increased—Etoposide—urinary bladder cancer	0.00119	0.00127	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—urinary bladder cancer	0.00119	0.00127	CcSEcCtD
Ceftazidime—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00119	0.00127	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00116	0.00124	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—urinary bladder cancer	0.00115	0.00123	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—urinary bladder cancer	0.00115	0.00123	CcSEcCtD
Ceftazidime—Dizziness—Fluorouracil—urinary bladder cancer	0.00115	0.00123	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00114	0.00122	CcSEcCtD
Ceftazidime—Diarrhoea—Cisplatin—urinary bladder cancer	0.00113	0.0012	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00112	0.0012	CcSEcCtD
Ceftazidime—Vomiting—Gemcitabine—urinary bladder cancer	0.00112	0.0012	CcSEcCtD
Ceftazidime—Rash—Gemcitabine—urinary bladder cancer	0.00111	0.00119	CcSEcCtD
Ceftazidime—Dermatitis—Gemcitabine—urinary bladder cancer	0.00111	0.00119	CcSEcCtD
Ceftazidime—Hypersensitivity—Etoposide—urinary bladder cancer	0.00111	0.00119	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00111	0.00118	CcSEcCtD
Ceftazidime—Headache—Gemcitabine—urinary bladder cancer	0.00111	0.00118	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—urinary bladder cancer	0.0011	0.00118	CcSEcCtD
Ceftazidime—Vomiting—Fluorouracil—urinary bladder cancer	0.0011	0.00118	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—urinary bladder cancer	0.0011	0.00118	CcSEcCtD
Ceftazidime—Rash—Fluorouracil—urinary bladder cancer	0.00109	0.00117	CcSEcCtD
Ceftazidime—Dermatitis—Fluorouracil—urinary bladder cancer	0.00109	0.00117	CcSEcCtD
Ceftazidime—Headache—Fluorouracil—urinary bladder cancer	0.00109	0.00116	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—urinary bladder cancer	0.00108	0.00116	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—urinary bladder cancer	0.00108	0.00115	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—urinary bladder cancer	0.00107	0.00115	CcSEcCtD
Ceftazidime—Pruritus—Etoposide—urinary bladder cancer	0.00107	0.00114	CcSEcCtD
Ceftazidime—Nausea—Gemcitabine—urinary bladder cancer	0.00105	0.00112	CcSEcCtD
Ceftazidime—Vomiting—Cisplatin—urinary bladder cancer	0.00105	0.00112	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—urinary bladder cancer	0.00104	0.00112	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00104	0.00111	CcSEcCtD
Ceftazidime—Rash—Cisplatin—urinary bladder cancer	0.00104	0.00111	CcSEcCtD
Ceftazidime—Dermatitis—Cisplatin—urinary bladder cancer	0.00104	0.00111	CcSEcCtD
Ceftazidime—Diarrhoea—Etoposide—urinary bladder cancer	0.00103	0.0011	CcSEcCtD
Ceftazidime—Nausea—Fluorouracil—urinary bladder cancer	0.00103	0.0011	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—urinary bladder cancer	0.00102	0.00109	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—urinary bladder cancer	0.00101	0.00108	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—urinary bladder cancer	0.000998	0.00107	CcSEcCtD
Ceftazidime—Dizziness—Etoposide—urinary bladder cancer	0.000996	0.00107	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000993	0.00106	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—urinary bladder cancer	0.00099	0.00106	CcSEcCtD
Ceftazidime—Nausea—Cisplatin—urinary bladder cancer	0.000977	0.00105	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—urinary bladder cancer	0.000975	0.00104	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—urinary bladder cancer	0.000958	0.00103	CcSEcCtD
Ceftazidime—Vomiting—Etoposide—urinary bladder cancer	0.000958	0.00103	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—urinary bladder cancer	0.000951	0.00102	CcSEcCtD
Ceftazidime—Rash—Etoposide—urinary bladder cancer	0.00095	0.00102	CcSEcCtD
Ceftazidime—Dermatitis—Etoposide—urinary bladder cancer	0.000949	0.00102	CcSEcCtD
Ceftazidime—Headache—Etoposide—urinary bladder cancer	0.000944	0.00101	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000938	0.001	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000935	0.001	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—urinary bladder cancer	0.000926	0.000991	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000902	0.000966	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—urinary bladder cancer	0.000902	0.000966	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—urinary bladder cancer	0.000897	0.00096	CcSEcCtD
Ceftazidime—Nausea—Etoposide—urinary bladder cancer	0.000895	0.000958	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000885	0.000947	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000884	0.000946	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—urinary bladder cancer	0.00088	0.000942	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—urinary bladder cancer	0.000877	0.000938	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000875	0.000936	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—urinary bladder cancer	0.000857	0.000917	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000844	0.000904	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—urinary bladder cancer	0.000843	0.000903	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—urinary bladder cancer	0.00083	0.000888	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000828	0.000886	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000827	0.000885	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—urinary bladder cancer	0.00082	0.000878	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—urinary bladder cancer	0.00081	0.000867	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00081	0.000866	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—urinary bladder cancer	0.000789	0.000845	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000781	0.000836	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000779	0.000834	CcSEcCtD
Ceftazidime—Pain—Methotrexate—urinary bladder cancer	0.000772	0.000826	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000766	0.00082	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000765	0.000819	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—urinary bladder cancer	0.000759	0.000812	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—urinary bladder cancer	0.000758	0.000812	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000738	0.00079	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—urinary bladder cancer	0.00073	0.000781	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000729	0.00078	CcSEcCtD
Ceftazidime—Pain—Epirubicin—urinary bladder cancer	0.000722	0.000773	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—urinary bladder cancer	0.000717	0.000767	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—urinary bladder cancer	0.000713	0.000764	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—urinary bladder cancer	0.000713	0.000764	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000702	0.000751	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000691	0.000739	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000675	0.000722	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—urinary bladder cancer	0.000671	0.000718	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—urinary bladder cancer	0.000668	0.000715	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—urinary bladder cancer	0.000668	0.000715	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—urinary bladder cancer	0.000668	0.000715	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000665	0.000712	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000639	0.000684	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—urinary bladder cancer	0.000638	0.000683	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000622	0.000666	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—urinary bladder cancer	0.000621	0.000664	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000618	0.000661	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000618	0.000661	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—urinary bladder cancer	0.000617	0.000661	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—urinary bladder cancer	0.000597	0.000639	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—urinary bladder cancer	0.000597	0.000639	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—urinary bladder cancer	0.000578	0.000618	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000576	0.000616	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—urinary bladder cancer	0.000574	0.000614	CcSEcCtD
Ceftazidime—Rash—Methotrexate—urinary bladder cancer	0.000569	0.000609	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—urinary bladder cancer	0.000568	0.000608	CcSEcCtD
Ceftazidime—Headache—Methotrexate—urinary bladder cancer	0.000565	0.000605	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—urinary bladder cancer	0.000558	0.000598	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—urinary bladder cancer	0.000553	0.000592	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—urinary bladder cancer	0.000537	0.000575	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—urinary bladder cancer	0.000536	0.000574	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000535	0.000572	CcSEcCtD
Ceftazidime—Rash—Epirubicin—urinary bladder cancer	0.000532	0.00057	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—urinary bladder cancer	0.000532	0.000569	CcSEcCtD
Ceftazidime—Headache—Epirubicin—urinary bladder cancer	0.000529	0.000566	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—urinary bladder cancer	0.000517	0.000553	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—urinary bladder cancer	0.000502	0.000537	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—urinary bladder cancer	0.000497	0.000532	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—urinary bladder cancer	0.000493	0.000527	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—urinary bladder cancer	0.000492	0.000527	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—urinary bladder cancer	0.00049	0.000524	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—urinary bladder cancer	0.000464	0.000497	CcSEcCtD
